PHARMAESSENTIA’S BESREMi® (ROPEGINTERFERON ALFA-2B-NJFT) NOW AVAILABLE FOR THE TREATMENT OF PEOPLE WITH POLYCYTHEMIA VERA IN THE UNITED STATES
BESREMi® is the only therapy indicated for adults with PV regardless of treatment history
PharmaEssentia introduces holistic services program to support prescribed patients
December 6, 2021, Burlington, MA – PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that BESREMi® (ropeginterferon alfa-2b-njft) is now commercially available in the U.S. to eligible patients with polycythemia vera (PV). BESREMi was approved by the FDA in November as the only interferon for adults with polycythemia vera. BESREMi was approved with a boxed warning for risk of serious disorders including aggravation of neuropsychiatric, autoimmune, ischemic and infectious disorders.
“Today marks the beginning of a new chapter in the treatment of PV. Our team is delivering on our goal to bring an innovative solution that may help more people manage not only the symptoms of PV, but target the disease itself to gain durable control with potential to reduce progression over time,” said Meredith Manning, U.S. General Manager. “We look forward to working closely with U.S. providers to raise awareness of this therapy and help advance treatment goals.”
PharmaEssentia SOURCE Now Available to Support People with PV in the U.S.
With the commercial availability of BESREMi, PharmaEssentia is also launching a comprehensive patient support program, which can be found at www.pharmaessentiaSOURCE.com.